Venetoclax combined with azacitidine in the treatment of newly diagnosed chronic myelomonocytic leukemia-2: report of 4 cases and review of literature
10.3760/cma.j.cn115356-20230616-00133
- VernacularTitle:维奈克拉联合阿扎胞苷治疗初诊慢性粒单核细胞白血病2型4例并文献复习
- Author:
Shaojie YE
1
;
Jianmei XU
;
Huimei GUO
;
Songying ZHAO
;
Jing WANG
;
Hua XUE
Author Information
1. 河北大学附属医院血液科，保定 071000
- Keywords:
Chronic myelomonocytic leukemia;
Venetoclax;
Azacitidine;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2023;32(11):667-670
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy of venetoclax plus azacitidine (VA) in the treatment of patients with newly diagnosed chronic myelomonocytic leukemia (CMML).Methods:The clinical data of 4 newly diagnosed CMML-2 patients treated with VA regimen in the Affiliated Hospital of Hebei University from February 2022 to March 2023 were retrospectively analyzed, and the related literature was reviewed.Results:All 4 CMML-2 patients achieved the effect of ≥ partial bone marrow remission (PMR) after 1 course of treatment, and with the deepened extension of treatment course, the overall response rate and complete remission (CR) rate was 100% and 50%, respectively. In terms of dose adjustment, the dose and usage day of venetoclax were determined by using dynamic frailty assessment and adverse events. Among the 2 patients who achieved CR, 1 patient initially received venetoclax 200 mg for 14 days, and 1 patient received venetoclax 400 mg for 28 days and then the usage reduced to venetoclax 200 mg for 14 days due to hematological adverse events. All 4 patients maintained CR status. The most common grade 3 and 4 adverse events were neutropenia and thrombocytopenia.Conclusions:The first-line application of VA regimen in the treatment of newly diagnosed CMML-2 patients may achieve faster remission and better safety compared with traditional HMA monotherapy.
